PER® Miami Breast Cancer Conference

Giuseppe Curigliano, MD, PhD, discusses the challenges of treatment sequencing in HER2-positive breast cancer with all the options currently available.

Findings presented at the Miami Breast Cancer Conference support using T-DXd across a wide range of real-world patients in community cancer settings.

Kevin Kalinsky, MD, MS, FASCO, notes insights from a molecular tumor board discussion about the optimal management of HR-positive metastatic breast cancer.

Meghan R. Flanagan, MD, MPH, noted the nuanced discussions that multidisciplinary tumor boards should have to optimize breast cancer management strategies.

Patricia Jakel, MSN, notes the factors that influence breast cancer care, as exemplified in a discussion at the 43rd Annual Miami Breast Cancer Conference.

Zovegalisib plus fulvestrant drove responses in HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer

Priyanka Sharma, MD, discusses potential neoadjuvant de-escalation strategies in HER2-positive breast cancer.

Lillian Rodich, MSPAS, MPH, highlights ways that medical oncologists can counsel patients with breast cancer about integrative medicine modalities.

W. Fraser Symmans, MD, discusses data on the current state of AI-driven digital pathology in HR+ breast cancer.

Heather A. Parsons, MD, MPH, shares growing evidence for the prognostic value of circulating tumor DNA in early-stage breast cancer.

Ultra-hypofractionted radiotherapy yielded responses in locally advanced breast cancer.

T-DXd was associated with low rates of real-world discontinuation in HER2-low metastatic breast cancer.

Find out which of this year’s Miami Breast presentations are anticipated to be “heard on Friday and used on Monday.”

ALISCA-Breast1 is investigating alisertib plus endocrine therapy in HR-positive, HER2-negative recurrent or metastatic breast cancer.

Neratinib-containing combinations are consistently effective across CNS end points in patients with HER2-positive breast cancer brain metastases.

Promising new agents are in development to address the unmet need resulting from resistance to endocrine therapy plus CDK4/6 inhibition in breast cancer.

Preliminary data showed atirmociclib plus letrozole yielded antitumor activity in HR-positive/HER2-negative metastatic breast cancer.

Sara A. Hurvitz, MD, FACP, discusses the growing role of systemic therapy in HER2-positive breast cancer brain metastases.

Patients with high-risk, early breast cancer receiving adjuvant abemaciclib maintained benefit with the agent regardless of dose modification.

Same-day administration of eflapegrastim and cycle 1 of chemotherapy reduced the mean duration of severe neutropenia in early-stage breast cancer.

Benefits were seen with abemaciclib/fulvestrant regardless of metastatic site in HER2-negative advanced breast cancer following prior CDK4/6 inhibition.

Patritumab deruxtecan elicited responses with acceptable safety in hormone receptor–positive, HER2-negative advanced breast cancer.

Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.

Sara M. Tolaney, MD, MPH, discusses considerations for the use of adjuvant CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer.

Palbociclib plus an AI prolonged OS and PFS in real-world patients with HR-positive/HER2-negative breast cancer from disadvantaged neighborhoods.

Sara A. Hurvitz, MD, FACP, offers insight on the use of (neo)adjuvant therapies in HER2-positive early breast cancer, and how to best optimize treatment.

PF-07248144 plus fulvestrant was safe and generated responses in pretreated estrogen receptor–positive, HER2-negative metastatic breast cancer.

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab provides meaningful OS benefits in high-risk, early-stage TNBC.